论文部分内容阅读
目的探究α-甲酰基辅酶A消旋酶(P504s)、高分子量角蛋白抗体(34βE12)与p65蛋白联合细胞角蛋白(CK5/6)对前列腺良恶性病变鉴别诊断的临床意义。方法前列腺组织标本144例,前列腺癌73例,前列腺增生71例,均采用免疫组化法检测P504s、p65、34βE12及CK5/6表达,比较P504s、p65、34βE12及CK5/6单一检测及联合检测前列腺癌结果。结果 P504s、p65、34βE12及CK5/6联合检测前列腺癌特异度为95.77%、灵敏度为84.93%、准确度为90.28%均高于单一检测,而误诊率4.23%、漏诊率15.07%均低于单一检测(P<0.05)。结论联合检测P504s、p65、34βE12及CK5/6表达,可显著提高诊断前列腺癌特异度、灵敏度、准确度,降低误诊率、漏诊率,有助于准确鉴别前列腺良恶性病变。
Objective To investigate the clinical significance of the differential diagnosis of benign and malignant prostatic diseases with α-formyl-CoA racemase (P504s), high molecular weight keratin antibody (34βE12) and p65 protein combined with cytokeratin (CK5 / 6). Methods 144 cases of prostatic tissue specimens, 73 cases of prostate cancer and 71 cases of benign prostatic hyperplasia were examined by immunohistochemistry. The expressions of P504s, p65, 34βE12 and CK5 / 6 were detected by immunohistochemical method. The single and combined detection of P504s, p65, 34βE12 and CK5 / 6 Prostate cancer results. Results The specificity of P504s, p65, 34βE12 and CK5 / 6 in detecting prostate cancer was 95.77%, the sensitivity was 84.93% and the accuracy was 90.28%, but the misdiagnosis rate was 4.23% and the rate of misdiagnosis was 15.07% Test (P <0.05). Conclusions Combined detection of P504s, p65, 34βE12 and CK5 / 6 expression can significantly improve the specificity, sensitivity and accuracy of diagnosis of prostate cancer, reduce the rate of misdiagnosis and misdiagnosis, and help identify the benign and malignant prostatic diseases.